米国企業
IRONWOOD PHARMACEUTICALS INC

IRONWOOD PHARMACEUTICALS INCIRWD

時価総額

$7.1億

PER

	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日
Cash and cash equivalents	87	137	75	74	261	54	126	173	177	363	620	656	92
Accounts receivable, net	0	0	1	0	3	1	3	21	11	122	114	115	129
Prepaid expenses and other current assets	3	8	6	11	6	9	7	11	11	9	9	8	12
Restricted cash	-	-	-	-	-	-	-	1	1	2	1	1	-
Convertible note hedges	-	-	-	-	-	-	-	-	-	-	1	-	-
Total current assets	168	184	229	290	500	380	312	266	307	496	745	781	233
Total current assets	168	184	229	290	500	380	312	266	307	496	745	781	233
Restricted Cash, Noncurrent	-	-	-	-	-	-	-	6	1	1	1	1	-
Accounts receivable, net of current portion	-	-	-	-	-	-	-	-	33	23	24	15	-
Property and equipment, net	34	38	37	30	21	21	17	17	12	9	8	6	6
Operating lease right-of-use assets	-	-	-	-	-	-	-	-	18	17	15	14	13
Deferred tax assets	-	-	-	-	-	-	-	-	-	-	333	284	212
Intangible assets, net	-	-	-	-	-	-	-	-	-	-	-	-	4
Other assets	0	0	4	6	3	1	1	0	0	1	1	1	4
Deferred tax assets	-	-	-	-	-	-	-	-	-	-	333	284	212
Total assets	209	230	279	334	619	710	606	332	403	559	1,127	1,101	471
Other assets	0	0	4	6	3	1	1	0	0	1	1	1	4
Total assets	209	230	279	334	619	710	606	332	403	559	1,127	1,101	471
Accounts payable	6	14	10	10	9	18	16	18	4	1	1	0	8
Accrued research and development costs	7	6	3	4	4	7	7	8	3	2	16	5	21
Accrued expenses and other current liabilities	-	-	-	-	23	38	38	45	30	26	24	17	44
Operating Lease, Liability, Current	-	-	-	-	-	-	-	-	1	3	3	3	3
Convertible Debt, Current	-	-	-	-	-	-	-	-	-	-	117	-	200
Note hedge warrants	-	-	-	-	-	-	-	-	-	-	1	0	-
Total current liabilities	65	55	41	61	76	91	66	120	41	32	162	26	276
Convertible Debt, Noncurrent	-	-	-	-	-	-	-	266	408	430	337	396	198
Operating Lease, Liability, Noncurrent	-	-	-	-	-	-	-	-	22	20	18	17	15
Other liabilities	-	1	2	-	10	8	5	3	1	2	4	10	28
Revolving credit facility	-	-	-	-	-	-	-	-	-	-	-	-	300
Other liabilities	-	1	2	-	10	8	5	3	1	2	4	10	28
Common Stock, Value, Issued	-	-	-	-	-	-	-	-	0	0	0	0	0
Additional paid-in capital	542	649	816	1,056	1,205	1,258	1,319	1,395	1,479	1,529	1,543	1,349	1,355
Accumulated deficit	-432	-505	-778	-967	-1,110	-1,192	-1,309	-1,591	-1,600	-1,500	-938	-696	-1,699
Total stockholders' equity (deficit)	110	144	38	89	95	67	10	-196	-93	63	606	652	-346
Accumulated other comprehensive loss	0	0	0	-0	-0	-0	-0	-	-	-	-	-	-3
Total stockholders' equity (deficit)	110	144	38	89	95	67	10	-196	-93	63	606	652	-346
Total liabilities and stockholders' equity	209	230	279	334	619	710	606	332	403	559	1,127	1,101	471
Common Stock, Value, Issued	-	-	-	-	-	-	-	-	0	0	0	0	0
Additional paid-in capital	542	649	816	1,056	1,205	1,258	1,319	1,395	1,479	1,529	1,543	1,349	1,355
Accumulated deficit	-432	-505	-778	-967	-1,110	-1,192	-1,309	-1,591	-1,600	-1,500	-938	-696	-1,699
Total stockholders' equity (deficit)	110	144	38	89	95	67	10	-196	-93	63	606	652	-346
Accumulated other comprehensive loss	0	0	0	-0	-0	-0	-0	-	-	-	-	-	-3
Total stockholders' equity (deficit)	110	144	38	89	95	67	10	-196	-93	63	606	652	-346
Total liabilities and stockholders' equity	209	230	279	334	619	710	606	332	403	559	1,127	1,101	471